205444-22-0Relevant articles and documents
NOVEL NON-SYSTEMIC TGR5 AGONISTS
-
Page/Page column 82, (2018/02/28)
The present invention relates to tricyclic compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present tricyclic compounds are useful non-sytemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing tricyclic compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.
Heteroaryl and benzyl amide compounds
-
Page/Page column 17, (2010/11/28)
Compounds of formula I wherein R1, R2, R4, R5, A, B, D and n are as defined, and pharmaceutically acceptable salts thereof, processes for their preparation, their use as pharmaceuticals and pharmaceutical compositions comprising them.
Halogen shuffling in pyridines: Site selective electrophilic substitutions of 2-chloro-6-(trifluoromethyl)pyridine
Mongin, Florence,Tognini, Antonio,Cottet, Fabrice,Schlosser, Manfred
, p. 1749 - 1752 (2007/10/03)
When treated with lithium diisopropylamide in tetrahydrofuran at -85 °C and subsequently with iodine, 2-chloro-6-(trifluoromethyl)pyridine is neatly converted into its 3-iodo derivative. The latter can be quantitatively isomerized to afford 2-chloro-4-iodo-6-(trifluoromethyl)pyridine. Either iodo compound can serve as the starting material for further manipulation in reaction sequences consisting of halogen/metal exchange and electrophilic trapping.